NYSE:DYN Dyne Therapeutics (DYN) Stock Forecast, Price & News $9.09 -0.18 (-1.94%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$8.91▼$9.3650-Day Range$9.09▼$12.1852-Week Range$8.04▼$15.60Volume292,696 shsAverage Volume497,019 shsMarket Capitalization$554.67 millionP/E RatioN/ADividend YieldN/APrice Target$27.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Dyne Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.20 Rating ScoreUpside/Downside199.2% Upside$27.20 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.10Based on 8 Articles This WeekInsider TradingSelling Shares$72,073 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.57) to ($3.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector279th out of 963 stocksPharmaceutical Preparations Industry116th out of 458 stocks 3.6 Analyst's Opinion Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.20, Dyne Therapeutics has a forecasted upside of 199.2% from its current price of $9.09.Amount of Analyst CoverageDyne Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DYN. Previous Next 0.0 Dividend Strength Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DYN. Previous Next 2.3 News and Social Media Coverage News SentimentDyne Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Dyne Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,073.00 in company stock.Percentage Held by Insiders32.89% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dyne Therapeutics are expected to grow in the coming year, from ($3.57) to ($3.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -2.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dyne Therapeutics (NYSE:DYN) StockDyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More DYN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DYN Stock News HeadlinesSeptember 22, 2023 | marketwatch.comDyne Therapeutics Gets New FDA Orphan Drug DesignationSeptember 22, 2023 | markets.businessinsider.comDyne Therapeutics's DYNE-101 Gets Orphan Drug Designation From FDASeptember 24, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 22, 2023 | msn.comDyne Therapeutics gets FDA orphan drug status for DM1 drugSeptember 22, 2023 | americanbankingnews.comDyne Therapeutics (NYSE:DYN) Shares Down 6.3% After Insider SellingSeptember 20, 2023 | finance.yahoo.comDyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1September 18, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Dyne Therapeutics (DYN)September 15, 2023 | finance.yahoo.comWhy Shares of Dyne Therapeutics Fell This WeekSeptember 24, 2023 | Legacy Research (Ad)Watch SHOCKING Footage of AI Facility with Ties to Elon MuskI recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.September 14, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Wildon Farwell Sells 1,707 Shares of Dyne Therapeutics IncSeptember 10, 2023 | msn.comDyne Therapeutics: Muscle Disease Oligo Therapy Developer In Early StagesSeptember 5, 2023 | finance.yahoo.comDyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare ConferenceAugust 24, 2023 | finance.yahoo.comCARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of DirectorsAugust 10, 2023 | msn.comJP Morgan Maintains Dyne Therapeutics (DYN) Overweight RecommendationAugust 3, 2023 | seekingalpha.comDyne Therapeutics GAAP EPS of -$1.08August 3, 2023 | finance.yahoo.comDyne Therapeutics Reports Second Quarter 2023 Financial Results and Business HighlightsJune 30, 2023 | markets.businessinsider.comParent Project Muscular Dystrophy Hosts 29th Annual Conference in Dallas, TexasJune 16, 2023 | finance.yahoo.com‘SMID Caps Are Poised for a Good Run,’ Says Oppenheimer — And These 2 Stocks Fit the Bill With Over 100% UpsideJune 1, 2023 | finance.yahoo.comDyne Therapeutics to Present at Jefferies Healthcare ConferenceMay 28, 2023 | msn.comDyne Therapeutics: FORCE Platform Poised To Revolutionize Gene TherapyMay 25, 2023 | msn.comDyne's muscle disorder therapy DYNE-101 gets orphan drug status in EUMay 25, 2023 | markets.businessinsider.comDyne Therapeutics' DYNE-101 Granted Orphan Drug Designation By EMAMay 25, 2023 | finance.yahoo.comDyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101May 17, 2023 | finance.yahoo.comWe're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn RateMay 17, 2023 | finance.yahoo.comDyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual MeetingMay 11, 2023 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsMay 11, 2023 | msn.comDyne Therapeutics: Q1 Earnings InsightsSee More Headlines Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees134Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.20 High Stock Price Forecast$34.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+199.2%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-168,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-79.63% Return on Assets-66.07% Debt Debt-to-Equity RatioN/A Current Ratio10.54 Quick Ratio10.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book1.88Miscellaneous Outstanding Shares61,020,000Free Float40,951,000Market Cap$554.67 million OptionableOptionable Beta0.16 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Joshua T. Brumm (Age 45)CEO, Pres & Director Comp: $946.5kMs. Susanna Gatti High M.B.A. (Age 55)Chief Operating Officer Comp: $655.5kDr. Oxana Beskrovnaya Ph.D. (Age 61)Chief Scientific Officer Comp: $631.08kDr. Romesh Subramanian Ph.D. (Age 58)Co-Founder & Advisor Mr. Richard William Scalzo M.B.A. (Age 36)Sr. VP and Head of Fin. & Admin. Mr. John Najim M.B.A.Chief Technical OfficerMs. Amy Reilly (Age 49)Sr. VP and Head of Corp. Communications & Investor Relations Mr. Daniel Wilson (Age 51)Sr. VP & Head of Legal Ms. Kate MitchellVP & Head of HRMs. Debra Feldman (Age 52)Chief Regulatory Affairs Officer More ExecutivesKey CompetitorsEntrada TherapeuticsNASDAQ:TRDAThorne HealthTechNASDAQ:THRNBiomea FusionNASDAQ:BMEAEvolusNASDAQ:EOLSWave Life SciencesNASDAQ:WVEView All CompetitorsInsiders & InstitutionsBarclays PLCBought 49,883 shares on 9/21/2023Ownership: 0.134%Susanna Gatti HighSold 2,672 sharesTotal: $25,143.52 ($9.41/share)Richard William ScalzoSold 1,290 sharesTotal: $12,138.90 ($9.41/share)Susanna Gatti HighSold 1,635 sharesTotal: $17,020.35 ($10.41/share)Wildon FarwellSold 1,707 sharesTotal: $17,769.87 ($10.41/share)View All Insider TransactionsView All Institutional Transactions DYN Stock - Frequently Asked Questions Should I buy or sell Dyne Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DYN shares. View DYN analyst ratings or view top-rated stocks. What is Dyne Therapeutics' stock price forecast for 2023? 5 Wall Street analysts have issued 12-month price objectives for Dyne Therapeutics' shares. Their DYN share price forecasts range from $20.00 to $34.00. On average, they anticipate the company's share price to reach $27.20 in the next year. This suggests a possible upside of 199.2% from the stock's current price. View analysts price targets for DYN or view top-rated stocks among Wall Street analysts. How have DYN shares performed in 2023? Dyne Therapeutics' stock was trading at $11.59 at the beginning of the year. Since then, DYN shares have decreased by 21.6% and is now trading at $9.09. View the best growth stocks for 2023 here. When is Dyne Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our DYN earnings forecast. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NYSE:DYN) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.27. What ETFs hold Dyne Therapeutics' stock? ETFs with the largest weight of Dyne Therapeutics (NYSE:DYN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Dyne Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dyne Therapeutics investors own include iShares Preferred and Income Securities ETF (PFF), Micron Technology (MU), IVERIC bio (OPHT), SentinelOne (S), Starbucks (SBUX), SunPower (SPWR), Apollo Investment (AINV), Argos Therapeutics (ARGSQ), Broadcom (AVGO) and Bausch Health Companies (BHC). When did Dyne Therapeutics IPO? (DYN) raised $175 million in an initial public offering on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel served as the underwriters for the IPO. What is Dyne Therapeutics' stock symbol? Dyne Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DYN." Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.44%), Deep Track Capital LP (4.10%), Wasatch Advisors LP (3.70%), VR Adviser LLC (3.56%), Goldman Sachs Group Inc. (3.29%) and Franklin Resources Inc. (3.14%). Insiders that own company stock include Jason P Rhodes, Jonathan Mcneill, Joshua T Brumm, Richard William Scalzo, Susanna Gatti High and Wildon Farwell. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dyne Therapeutics' stock price today? One share of DYN stock can currently be purchased for approximately $9.09. How much money does Dyne Therapeutics make? Dyne Therapeutics (NYSE:DYN) has a market capitalization of $554.67 million. The company earns $-168,100,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. How many employees does Dyne Therapeutics have? The company employs 134 workers across the globe. How can I contact Dyne Therapeutics? Dyne Therapeutics' mailing address is 1560 Trapelo Road, Waltham, MA 02451, United States. The official website for the company is www.dyne-tx.com. The company can be reached via phone at 781-786-8230, via email at ir@dyne-tx.com, or via fax at 781-786-8866. This page (NYSE:DYN) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.